Spyglass Pharma (NASDAQ:SGP) Sets New 12-Month High - Still a Buy?

Key Points

• Spyglass Pharma shares reached a new 52-week high, trading around $33.13 after rising 7.5%, giving the company a market capitalization of approximately $1.11 billion.
• Analyst sentiment is mixed but leans positive: seven analysts rate the stock a Buy, one rates it Hold, and one rates it Sell. The consensus rating is “Moderate Buy,” with a $44 average price target.
• The company remains in clinical development for an implantable drug-delivery system targeting glaucoma and ocular hypertension, while its latest quarterly loss of $0.59 per share missed the $0.48 consensus estimate.

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $32.85 and last traded at $33.1310, with a volume of 105,033 shares. The stock had previously closed at $30.90.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Weiss Ratings downgraded Spyglass Pharma from a "sell (e+)" rating to a "sell (e)" rating in a report on Friday, September 25th. UBS Group reissued a "buy" rating on shares of Spyglass Pharma in a research note on Monday, October 5th. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Spyglass Pharma in a report on Wednesday, October 21st. Wall Street Zen lowered shares of Spyglass Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, October 3rd. Finally, Raymond James Financial began coverage on shares of Spyglass Pharma in a report on Friday, August 14th. They issued an "outperform" rating and a $39.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $44.00.

Spyglass Pharma Stock Up 7.5%

The stock's fifty day moving average price is $26.86 and its 200-day moving average price is $24.12. The company has a market capitalization of $1.11 billion and a price-to-earnings ratio of -4.71.

Spyglass Pharma (NASDAQ:SGP - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.11). Analysts anticipate that Spyglass Pharma, Inc. will post -2.55 EPS for the current year.

Hedge Funds Weigh In On Spyglass Pharma

Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in Spyglass Pharma during the second quarter valued at approximately $533,000. Bank of America Corp DE bought a new stake in shares of Spyglass Pharma during the 1st quarter worth approximately $726,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Spyglass Pharma in the 1st quarter valued at approximately $308,000. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma in the 1st quarter valued at approximately $9,716,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Spyglass Pharma in the first quarter valued at $6,478,000.

About Spyglass Pharma

SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company's platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.

SpyGlass Pharma's lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.

The company is advancing its technology through clinical development and regulatory processes in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.